TherapeuticsMD, Inc. Quarterly Comprehensive Income (Loss), Net of Tax, Attributable to Parent in USD from Q1 2021 to Q4 2023
-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.
-
Summary
-
TherapeuticsMD, Inc. quarterly/annual Comprehensive Income (Loss), Net of Tax, Attributable to Parent history and growth rate from Q1 2021 to Q4 2023.
- TherapeuticsMD, Inc. Comprehensive Income (Loss), Net of Tax, Attributable to Parent for the quarter ending December 31, 2023 was -$883K, a 101% decline year-over-year.
- TherapeuticsMD, Inc. Comprehensive Income (Loss), Net of Tax, Attributable to Parent for the twelve months ending December 31, 2023 was -$10.3M, a 109% decline year-over-year.
- TherapeuticsMD, Inc. annual Comprehensive Income (Loss), Net of Tax, Attributable to Parent for 2023 was -$10.3M, a 109% decline from 2022.
- TherapeuticsMD, Inc. annual Comprehensive Income (Loss), Net of Tax, Attributable to Parent for 2022 was $112M.
- TherapeuticsMD, Inc. annual Comprehensive Income (Loss), Net of Tax, Attributable to Parent for 2021 was -$172M, a 6.05% increase from 2020.
Comprehensive Income (Loss), Net of Tax, Attributable to Parent, Trailing 12 Months (USD)
Comprehensive Income (Loss), Net of Tax, Attributable to Parent, Quarterly (USD)
Comprehensive Income (Loss), Net of Tax, Attributable to Parent, YoY Quarterly Growth (%)